MedPath

SEELOS THERAPEUTICS INC

SEELOS THERAPEUTICS INC logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
$1.9M
Website

Clinical Trials

4

Active:0
Completed:1

Trial Phases

1 Phases

Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (100.0%)

Intermediate-Sized Expanded Access Study

Conditions
Amyotrophic Lateral Sclerosis
First Posted Date
2022-10-28
Last Posted Date
2025-08-17
Lead Sponsor
Seelos Therapeutics, Inc.
Registration Number
NCT05597436
Locations
🇺🇸

Barrow Neurological Institute, Phoenix, Arizona, United States

🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

University of Colorado, Aurora, Colorado, United States

and more 14 locations

STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

Phase 2
Terminated
Conditions
Spinocerebellar Ataxia Type 3
Interventions
Drug: Placebo
First Posted Date
2022-08-05
Last Posted Date
2024-04-24
Lead Sponsor
Seelos Therapeutics, Inc.
Target Recruit Count
23
Registration Number
NCT05490563
Locations
🇺🇸

UCLA, Los Angeles, California, United States

🇺🇸

UCHealth Neurosciences Center - Anschutz Medical Campus, Aurora, Colorado, United States

🇺🇸

University of South Florida, Tampa, Florida, United States

and more 20 locations

SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease

Phase 2
Withdrawn
Conditions
Alzheimer's Disease
Interventions
Drug: SLS-005 - Twice Weekly
Drug: SLS-005 - Once Weekly
First Posted Date
2022-04-18
Last Posted Date
2023-04-11
Lead Sponsor
Seelos Therapeutics, Inc.
Registration Number
NCT05332678
Locations
🇦🇺

Austin Health, Heidelberg, Victoria, Australia

🇦🇺

Goulburn Valley Health, Shepparton, Victoria, Australia

🇦🇺

Neurodegenerative Disorders Research Pty Ltd, West Perth, Western Australia, Australia

A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide

Phase 2
Completed
Conditions
Depressive Disorder, Major
Suicidal
Interventions
Drug: Placebo
Other: Standard of care
Device: Intranasal device
First Posted Date
2020-12-17
Last Posted Date
2023-09-28
Lead Sponsor
Seelos Therapeutics, Inc.
Target Recruit Count
164
Registration Number
NCT04669665
Locations
🇺🇸

Seelos Investigational Site, Morgantown, West Virginia, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.